Novartis Evaluating Submission Strategy for Painkiller Prexige in Various Countries Except US

Despite a report that Novartis intends to resubmit its application for the painkiller Prexige to the US Food and Drug Administration with a companion genetic test, the Swiss drugmaker says it is not trying to relaunch the drug in the US market.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories